BioPartnering North America

BioPartnering North America

January 18, 2006 13:21 ET

BioPartnering North America 'BPN' Attracts Top Speakers and Delegates from the International Biotech Industry

SANTA CRUZ, CALIFORNIA--(CCNMatthews - Jan. 18, 2006) - Technology Vision Group LLC

There is now less than a month to go until this year's BioPartnering North America (BPN: http://www.techvision.com/bpn/) which will be held in Vancouver, B.C., Canada, on February 5-7, 2006 as a partnership between Technology Vision Group LLC (TVG), BC Biotech, BioAlberta and BIOTECanada. With well over 650 delegates from Europe, the US and Asia now registered to attend, the 4th annual BPN conference is proving to be as popular as ever, attracting key decision makers from the biotechnology, pharmaceutical and financial industries and providing the perfect platform for biotech companies seeking potential partners and business opportunities.

Topical debate from industry leaders

This year BPN will feature top level discussion and perspectives from big pharma on the state of the biotech industry today, as well as the evolving relationship between pharma and biotech companies. In particular senior executives from a number of pharma companies will discuss the following issues in the BioPartnering Leadership Sessions:

- Deal-making in Biotechnology: A State of the Industry Review

- Why Pharma and Biotech Need Each Other Now More than Ever

- Early Stage Deals: A Pharma Perspective

Ms Barbara Kosacz, Partner, Head of Life Sciences Practice at Cooley Godward LLP, who is chairing one of the sessions commented, "BPN provides an excellent opportunity for pharma and biotech companies to keep up to date with the latest partnering trends and strategies. The sessions provide valuable insights into the way pharma and biotech approach partnering deals with practical advice from experienced industry professionals."

Other pharmaceutical companies attending BPN include; Angiotech Pharmaceuticals Inc., Bayer, Boehringer Ingelheim, Bristol-Myers Squib, GlaxoSmithKline, Hoffmann-La Roche, Johnson & Johnson, Merck & Co., Novartis Pharmaceuticals Corp., Pfizer and Wyeth.

Global focus

BPN's program will also focus on the increasing importance of India and Japan where new centers of biotech/pharma excellence and large-scale markets have emerged in recent years. Discussions will include:

- An Industry Workshop called, "Partnering with Japanese Companies: A Global Link" which will offer attendees the opportunity to learn how to effectively develop relationships and execute deals with Japanese pharmaceutical companies and venture capitalists.

- A BioPartnering Leadership Session called, "The Burgeoning Influence of India and Japan: Trans-Pacific Deal Trends" in which a panel of experts who have done deals in these regions will discuss the deal process as well as the strategic thinking behind those transactions. Co-chair of the session, Mr Robert C. Rech, Managing Director of Ferghana Partners Group commented:

"This session will provide insider information for any European or US company planning on embarking on a partnership with a Japanese or an Indian company. With the increasing globalization of the biotech industry due to these new and growing markets it's an opportunity that delegates cannot afford to miss."

This year BPN will feature 5 BioPartnering Leadership Sessions, 6 workshops, 76 company presentations and 4 networking receptions that aim to highlight the current issues and trends in the biotech industry, as well as providing delegates with an innovative way to do business based on BPN's state-of-the-art biopartnering system, www.biopartnering.com.

Registrations are still being accepted for BPN at http://www.techvision.com/bpn/registration/

Media registration is now available and is complimentary for accredited members of the news media. To register for BPN, or for further information please contact Helena Podd or Valerie Auffray (Helena.podd@citigatdr.co.uk; Valerie.auffray@citigatedr.co.uk) at Citigate Dewe Rogerson.

Conference Sponsors

Angiotech Pharmaceuticals, Inc., AstraZeneca, PricewaterhouseCoopers LLP, Burrill & Company, Cooley Godward LLP, Farris, Vaughan, Wills & Murphy LLP, Ferghana Partners Group, Morrison & Foerster, Bristol-Myers Squibb Company, Life Science Analytics, Inc., Merck, Novartis, Pfizer, QLT Inc., Roche, Seed I.P. Law Group PLLC, UK Trade & Investment, Alberta Innovation & Science, Dorsey & Whitney, Forbes Medi-Tech Inc., Genome British Columbia, Gowlings, Japan External Trade Organization, Marsh Canada Limited, Quintiles Transnational Corp., Torys LLP, and UBC University-Industry Liaison Office

Conference Supporters

BioBusiness, BioExecutive, Biotechnology Focus, BioWorld Today, CCNMatthews, Citigate Dewe Rogerson, Contact Canada, Global Bioscience Partnership, International Trade Canada, Nature Biotechnology, Red Herring, and WBBA

2006 Emerging Company Presenters

4 AZA Bioscience, Acologix, Inc., Adnavance Technologies, Inc., AerovectRx Corporation, Alder Biopharmaceuticals, Antibe Therapeutics Inc.,AquaGenvx Pharmaceuticals, Cardiome Pharma Corp., EcoBiotics, Evolva AG, iCo Therapeutics Inc., KAI Pharmaceuticals, Nerites Corporation, Nura Inc., PainCeptor Pharma, Predix Pharmaceuticals, Reata Pharmaceuticals, Inc., Replikun Biotech Pty Limited, Talisker Pharma Ltd., and Vitae Pharmaceuticals, Inc.

2006 Open House Presenters

Alchemia Limited, Allon Therapeutics Inc., Alphora Research Inc., Antisoma, Atugen AG, Avidex Ltd., Biolex Theraputics, BioWa, Inc., Boston Life Sciences, Inc., CANTEST BioPharma Services, Celator Pharmaceuticals, Cell Signals Inc., Corgentech, Curis, Inc., Engene Inc., Evolutec Group Plc, Forbes Medi-Tech Inc., ImaRx Therapeutics, Inc., Ingenium Pharmaceuticals, Inimex Pharmaceuticals, Inc., InNexus Biotech, Jiangsu Simcere Pharmaceutical R&D Co., Ltd., Liponex Inc., MaxCyte, Inc., Medicago Inc., Meristem Therapeutics, Miltenyi Bioprocess, Novacta Biosystems Ltd., NovaDel Pharma, Novozymes A/S, Nycomed, Oncolytics Biotech Inc., Oxford BioMedica, Paradigm Therapeutics Ltd., Patheon Inc., Pharmacyclics, Product Safety Labs, Protox Therapeutics, PTC Therapeutics, Inc., QSV Biologics Limited, Santaris Pharma, SemBioSys Genetics, Stem Cell Therapeutics Corp., TopoTarget UK Ltd., Torcan Chemical Ltd., ToxTest, Transition Therapeutics Inc., Trigen Holdings AG, Trophos, Urigen, Xantos Biomedicine AG, XOMA Ltd., and YM BioSciences Inc.


Contact Information